Cargando…

TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks

53BP1 promotes nonhomologous end joining (NHEJ) over homologous recombination (HR) repair by mediating inactivation of DNA end resection. Ubiquitination plays an important role in regulating dissociation of 53BP1 from DNA double-strand breaks (DSBs). However, how this process is regulated remains po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Jian, Zhou, Yingke, Pan, Penglin, Yu, Haixin, Wang, Zixi, Li, Lei Lily, Wang, Bing, Yan, Yuqian, Pan, Yunqian, Ye, Qi, Liu, Tianjie, Feng, Xiaoyu, Xu, Shan, Wang, Ke, Wang, Xinyang, Jian, Yanlin, Ma, Bohan, Fan, Yizeng, Gao, Yang, Huang, Haojie, Li, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066190/ https://www.ncbi.nlm.nih.gov/pubmed/37002234 http://dx.doi.org/10.1038/s41467-023-37499-5

Ejemplares similares

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
por: Ma, Bohan, et al.
Publicado: (2022)

Deubiquitinase OTUD5 modulates mTORC1 signaling to promote bladder cancer progression
por: Hou, Tao, et al.
Publicado: (2022)

Identification Of Small Molecule TRABID Deubiquitinase Inhibitors By Computation-Based Virtual Screen
por: Shi, Tong, et al.
Publicado: (2012)

ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication
por: Wang, Dejie, et al.
Publicado: (2021)

An Ankyrin-repeat ubiquitin binding domain determines TRABID’s specificity for atypical ubiquitin chains
por: Licchesi, Julien D.F., et al.
Publicado: (2011)

EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma
por: Xu, Shan, et al.
Publicado: (2023)

Epigenetic regulation of Il12 and Il23 gene expression and autoimmune inflammation by the deubiquitinase Trabid
por: Jin, Jin, et al.
Publicado: (2016)

TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation
por: Chen, Yu-Hsuan, et al.
Publicado: (2023)

Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
por: An, Liwei, et al.
Publicado: (2022)

Co-targeting WIP1 and PARP induces synthetic lethality in hepatocellular carcinoma
por: Chen, Miaoqin, et al.
Publicado: (2022)

The deubiquitinase TRABID stabilizes the K29/K48-specific E3 ubiquitin ligase HECTD1
por: Harris, Lee D., et al.
Publicado: (2021)

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
por: Li, Shuangying, et al.
Publicado: (2022)

HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer
por: Pan, Penglin, et al.
Publicado: (2022)

Trabid inhibits hepatocellular carcinoma growth and metastasis by cleaving RNF8-induced K63 ubiquitination of Twist1
por: Zhu, Yuekun, et al.
Publicado: (2018)

RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis
por: Bai, Yang, et al.
Publicado: (2019)

Loss of Trabid, a New Negative Regulator of the Drosophila Immune-Deficiency Pathway at the Level of TAK1, Reduces Life Span
por: Fernando, Merennege Dilan Anush, et al.
Publicado: (2014)

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators
por: McLellan, Jessica L., et al.
Publicado: (2012)

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer
por: Zhou, Yingke, et al.
Publicado: (2022)

The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2019)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

VPS34 K29/K48 branched ubiquitination governed by UBE3C and TRABID regulates autophagy, proteostasis and liver metabolism
por: Chen, Yu-Hsuan, et al.
Publicado: (2021)

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition
por: Ma, Jian, et al.
Publicado: (2021)

In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment
por: Li, Jian, et al.
Publicado: (2016)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
por: Shao, Jingwei, et al.
Publicado: (2021)

Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia
por: Brabson, John P., et al.
Publicado: (2023)

Tetrandrine inhibits migration and invasion of human renal cell carcinoma by regulating Akt/NF-κB/MMP-9 signaling
por: Chen, Shurui, et al.
Publicado: (2017)

Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine
por: Murata, Stephen, et al.
Publicado: (2016)

Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors
por: Angers, Stephane
Publicado: (2021)

Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
por: Le, Bac Viet, et al.
Publicado: (2022)

Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer
por: Ma, Linlin, et al.
Publicado: (2019)

DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition
por: Viera, Talysa, et al.
Publicado: (2020)

Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression
por: Yang, Jing, et al.
Publicado: (2017)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
por: Asim, Mohammad, et al.
Publicado: (2017)

Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer
por: Li, Peng, et al.
Publicado: (2023)

miR-26b-5p promotes osteogenesis of bone mesenchymal stem cells via suppressing FGF21
por: Wang, Bin, et al.
Publicado: (2023)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_12bi6qajmrec4dc33rn3naa7ge